Introduction There is a lack of consensus regarding the surgical management of advanced-stage endometrial cancer. We aim to look at survival outcomes of advanced-stage carcinoma endometrium, managed through surgery and adjuvant treatment.
Methods This was a retrospective study from a tertiary care cancer centre in India that included all women registered between 1st August 2011 and 31st January 2021 with operable advanced-stage carcinoma endometrium (stages 3 and 4). Their relevant data were collected from electronic medical records.
Results Out of 1760 endometrial cancer cases screened 102 women with stage 3 and 4 disease were operable. The mean age was 59 years. Most women were parous (85%) with an ECOG status of 0 or 1 (90%). Histopathology was high grade in 73 women (71.6%). Surgeries performed were: Staging surgery 50(49%), debulking surgery 38(37.2%), surgery after chemotherapy 6(5.8%). Eight women (7.8%) were operable but given only chemotherapy for various reasons. 72 (76.6%) patients received planned adjuvant treatment. Overall, 50 patients (56.8%) were upstaged after surgery. At the time of analysis, 32 (31.4%) women were alive without disease. Median disease-free survival of stage 3, stage 4 and both combined were 32.8 months (95%CI: 0–87), 19 months (7.6–30.3), and 23.5 months (95% CI: 13.7–33.2) respectively. Median overall survival was not reached for stage 3. For stage 4 and both combined, it was 41 months (95% CI: 18.8–63.1) and 50.1 months (95% CI: 31.2–69.1) respectively.
Conclusion/Implications Upfront surgery in advanced-stage endometrial carcinoma gives a respectable survival outcome after maximal surgical attempt.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.